Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 16/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5186257 | 0.96 | TSPO (0.58) | TSPOLMNAHPGDPSEN1PSEN2 | |
| SCHEMBL5185075 | 0.93 | TSPO (0.60) | TSPOPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5185433 | 0.93 | TSPO (0.55) | TSPOLMNAHPGDPSEN1PSEN2 | |
| SCHEMBL5187781 | 0.90 | TSPO (0.54) | TSPOLMNAHPGDPSEN1PSEN2 | |
| SCHEMBL5187768 | 0.89 | TSPO (0.64) | TSPOHPGDPSEN1PSEN2APH1B | |
| SCHEMBL5185092 | 0.87 | TSPO (0.56) | TSPOHPGD | |
| SCHEMBL5186270 | 0.85 | TSPO (0.58) | TSPOHPGD | |
| SCHEMBL5186244 | 0.85 | TSPO (0.62) | TSPO | |
| SCHEMBL5186927 | 0.85 | TSPO (0.62) | TSPO | |
| SCHEMBL5186838 | 0.81 | KDM4E (0.66) | TSPOPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293558-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | claimed |
| EP-1802299-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2007-07-04 | — | — | EP | claimed |
| WO-2006044425-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | claimed |
| US-20070293558-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| EP-1802299-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044425-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293558-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNH2, KCNJ11, KCNN1 | TSPO 936/4885LMNA 351/4885HPGD 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.